Hainan Shuangcheng Pharmaceuticals (002693.SZ) is expected to incur losses and have revenues of less than 300 million yuan in 2024. After disclosing its annual report, it may face the risk of being delisted.

Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that it expects a net loss attributable to shareholders of the listed company of 55-80 million RMB in 2024, with a net loss of 58.37-83.37 million RMB after deducting non-recurring gains and losses, and operating income of 150-190 million RMB. According to the preliminary calculations of the company's financial department, the company is expected to have a negative net profit attributable to shareholders of the listed company and operating income below 300 million RMB in 2024. In accordance with the relevant provisions of the Shenzhen Stock Exchange's Stock Listing Rules, the company's stock trading may be subject to delisting risk warning (the stock symbol will have "*ST" as a prefix) after the disclosure of the 2024 annual report.